Influence of an acidic beverage on the absorption of erlotinib

Influence of an acidic beverage on the absorption of erlotinib - cola-study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40431

Enrollment

Registered

2014-02-05

Start date

2014-03-18

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

The intake of coca-cola

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years 2. Use of Erlotinib monotherapy for at least 4 weeks 3. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations

Exclusion criteria

Exclusion criteria: 1. Age

Design outcomes

Primary

Measure	Time frame
Differences in erlotinib bioavailability during coca-cola intake vs. water intake.	—

Secondary

Measure	Time frame
To compare the incidence and severity of side-effects of treatment with erlotinib in absence and presence of Coca-Cola.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)